ORIGINAL ARTICLE

An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children

J Diepstraten1, V Chidambaran2,3, S Sadhasivam2,3, HJ Blussé van Oud-Alblas4, T Inge5, B van Ramshorst6, EPA van Dongen7, AA Vinks3,8 and CAJ Knibbe1,9

This study describes a population pharmacokinetic meta-analysis of propofol to characterize the influence of body size and age in morbidly obese and nonobese adults, adolescents, and children. Sixty morbidly obese and nonobese adult patients (55–167 kg; 21–79 years) and 34 morbidly obese and nonobese adolescents and children (37–184 kg; 9–20 years) were included. The results show that clearance increased with total body weight in an allometric function while age was found to influence clearance in a bilinear fashion with two distinct slopes, reflecting an initial increase and subsequent decrease as a result of aging. Using these two functions, the influence of both (over)weight and age on propofol clearance was well characterized, which may provide a basis for dosing across this diverse group of patients.

CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e73; doi:10.1038/psp.2013.47; published online 11 September 2013

BACKGROUND

Although total body weight (TBW) of children and adolescents increases due to growth-related processes across childhood, obesity may also substantially contribute to increases in body weight.1 As a result, morbidly obese children and adolescents may be as heavy as adults, even though growth-related processes have not yet been completed. The question then arises whether TBW, which is commonly used to adjust dosing in children and adolescents, is the appropriate measure to adjust doses of drugs in obese children and adolescents. Similarly for adults, there is a lively discussion about the best size descriptor for changes in pharmacokinetics due to obesity.2,2 As little is known on how key pharmacokinetic parameters such as clearance change in morbidly obese children, adolescents, and adults as compared with their nonobese counterparts, studies are needed analyzing a wide range of ages and related TBWs.

Propofol is widely used for induction and maintenance of anesthesia in both nonobese and (morbidly) obese adults, adolescents, and children. Recently, the pharmacokinetics of propofol have been compared in premature neonates and adults,4 in morbidly obese and obese adults,5,6 and in (morbidly) obese children and adolescents.7 In all these studies, TBW proved the most predictive covariate for clearance, either by using a standard allometric function6–7 or a TBW-dependent exponent allometric function.6 However, a meta-analysis on the basis of all data sets in morbidly obese adults, adolescents, and children together with their nonobese controls in which the influence of obesity and ageing is disentangled has not been performed.

Therefore, the aim of this study was to perform a population pharmacokinetic meta-analysis of propofol combining data from morbidly obese and nonobese adults, adolescents, and children. To study how obesity and age influence pharmacokinetic parameter estimates in this diverse patient group, specific emphasis was placed on the evaluation of the influence of TBW, body mass index, ideal body weight,6 lean body weight (LBW),5,10 and/or age on the different pharmacokinetic parameters.

RESULTS

Subjects

Ninety-four adults, adolescents, and children with a mean TBW of 94 kg (range: 37–184 kg) were included from which 1,652 concentration measurements were available. Demographic characteristics of the morbidly obese and nonobese patients are summarized in Table 1.

Pharmacokinetics

A three-compartment pharmacokinetic model adequately described the time course of the propofol whole-blood concentrations in all morbidly obese and nonobese adults, adolescents, and children. Exploratory plots of the tested covariates TBW, body mass index, ideal body weight, LBW, and age against individual post hoc parameter estimates of the simple model without covariates (model A) showed a potential relation between clearance and TBW, with lower values for children and adolescents across the entire body weight range (Figure 1, model A). In addition, potential relationships were observed between central volume of distribution (V1) and...
TBW or LBW, and between intercompartmental clearance from the central to the second peripheral compartment (Q3) and TBW (figures not shown). There were no visual trends between the explored covariates and other pharmacokinetic parameters in the simple model without covariates (model A).

Subsequently, as depicted in Table 2, all body size measures and age were separately incorporated on clearance, V1, and Q3 in the model and tested for significance (see section Covariate analysis). The analysis showed that TBW was the most predictive covariate for propofol clearance when implemented using an allometric function (model B, decrease in objective function value (OFV) of 84.4 points; \( P < 0.001 \); Table 2). Figure 1 model B (and model A) shows that adolescents with the same TBW as adults had lower clearance values (gray vs. black symbols, respectively). Therefore, in model C, a separate value for propofol clearance in adolescents vs. adults was estimated. This resulted in another reduction in OFV by 23.5 points (\( P < 0.001 \)) with individual clearance values for an adolescent of 70 kg and an adult of 70 kg of 1.75 ml/min and 2.18 ml/min, respectively (Table 2, Model C). The nonlinear increase of propofol clearance with TBW proved the same for both groups and was best described using an allometric function with an estimated exponent of 0.73 (coefficients of variation percentage: 6.9) (Figure 1, Model C).

However, when the simple model without covariates was evaluated for the effect of age (Figure 2, model A), it was found that clearance increased until the median age of 41

Table 1 Baseline characteristics of all morbidly obese and nonobese adults, adolescents, and children included in the current analysis

|                | All Patients | Morbidly obese\(^a\) | Nonobese\(^a\)\(^b\)\(^c\) | Obese\(^7\) | Nonobese\(^7\)\(^c\) |
|----------------|--------------|----------------------|---------------------------|-------------|---------------------|
| Number         | 94           | 20                   | 40                        | 20          | 14                  |
| Gender (M/F)   | 30/64        | 4/16                 | 16/24                     | 8/12        | 2/12                |
| Age (years)    | 38 (20)      | 45 (12)              | 55 (12)                   | 16 (2)      | 14 (3)              |
| TBW (kg)       | 94 (35)      | 124 (20)             | 74 (11)                   | 125 (29)    | 54 (13)             |
| BMI (kg/m\(^2\)) | 33 (12)   | 43 (6)               | 26 (4)                    | 46 (9)      | 21 (6)              |
| IBW (kg)       | 61 (9)       | 61 (7)               | 64 (8)                    | 59 (12)     | 55 (9)              |
| LBW (kg)       | 54 (14)      | 60 (9)               | 50 (10)                   | 63 (14)     | 37 (8)              |

Data are presented as mean with standard deviation (SD).
BMI, body mass index; F, female; IBW, ideal body weight; \(^a\)LBW, lean body weight; \(^b\)M, male; SD, standard deviation; TBW, total body weight.

Figure 1 Individual post hoc propofol clearance estimates vs. total body weight for the simple model (model A) and three covariate pharmacokinetic models (B, C, and D) for morbidly obese adults (black circles), adolescents and children (gray circles) and their nonobese controls \((n = 94)\). In model B, the black line indicates the population clearance values for both the adult and adolescent population; in model C, the black line indicates the population clearance values for adults and the gray line the population clearance values for adolescents; and in model D, the black dotted lines indicate the population clearance values for 15, 41, and 65 years.
years after which it decreased. As a result, instead of estimation of two different population values for adolescents vs. adults as in model C, in model D, age was implemented using a bilinear function which significantly reduced the OFV (ΔOFV as compared with model C = −8.2 points; \( P < 0.005 \)). On the basis of the covariates of model D, the interindividual variability of propofol clearance was reduced by 50%. **Figure 2** model E shows that after implementation of age in a bilinear function, interindividual variability was randomly distributed with age. **Figure 1**, model D shows the post hoc propofol clearance estimates for model D vs. TBW with population predictions for clearance for three different ages (15, 41, and 65 years), illustrating the bilinear relation with age in model D. The final equation for propofol clearance was given as follows (Eq. 1):

\[
CL_i = CL_{\text{pop}} \times (TBW/70)^{0.77} \times F_{\text{age}}^a
\]

where \( CL_i \) represents clearance in the \( i \)th individual, \( CL_{\text{pop}} \) is the population mean value for clearance in an individual of 70 kg and of 41 years, \( TBW_i \) is the TBW of the \( i \)th individual, and 70 is the standard body weight in kilograms.

Concerning covariates for V1, **Table 2** shows that there was only a modest influence of the body size descriptors on V1 with a trend toward an increase in V1 with LBW (\( P > 0.005 \)). There was a substantial shrinkage (43%) on V1, which not only renders plots using post hoc parameter estimates less reliable but also indicates that the individual data in the data sets are not rich in information about this parameter. Therefore, no covariate on V1 was incorporated in the final model. By contrast, TBW as covariate for Q3 significantly improved

---

**Table 2** Results of covariate analysis for the three-compartment pharmacokinetic model of propofol in the combined data set of morbidly obese and nonobese adults, adolescents, and children

| Parameter | Model | Model description | Relationship of covariate | Number of structural parameters | ΔOFV |
|-----------|-------|-------------------|--------------------------|---------------------------------|------|
| CL        | A     | Simple model      | -                        | 11                              | -    |
| CL        | B     | LBW (9) linear    | CL = CL_{\text{pop}} \times (LBW/60) | 11                              | -45.8 |
| CL        | D     | TBW allometric    | CL = CL_{\text{pop,adults}} \times (TBW/70)^a | 14                              | -116.1 |
| V1        | E     | TBW allometric    | V1 = V1_{\text{pop}} \times (TBW/70) | 11                              | -0.2  |
| Q3        |       | TBW allometric    | Q3 = Q3_{\text{pop}} \times (TBW/70) | 11                              | -18.1 |
| Final model | E     | TBW allometric and age bilinear | CL = CL_{\text{pop}} \times (TBW/70)^a \times F_{\text{age}}^a \times (TBW/70)^z | 14                              | -143.0 |

*Age ≤ 41 years: \( F_{\text{age}} = (1 + b \times (Age - 41)) \) and Age > 41 years: \( F_{\text{age}} = (1 + c \times (Age - 41)) \). CL, clearance; \( CL_i \), clearance in \( i \)th individual; \( CL_{\text{pop}} \), population mean value for clearance; \( F_{\text{age}} \), age factor for clearance; LBW, lean body weight; ΔOFV, delta objective function value as compared with simple model; Q3, compartmental clearance between V1 and V3; TBW, total body weight; V1, central volume of distribution; z, allometric scaling factor in \( CL_i = CL_{\text{pop}} \times (TBW/70)^z \).
the model ($\Delta$OFV = −18.1; $P < 0.005$; Table 2) and was therefore considered the final model (Table 2, model E). There was no influence of the explored covariates on the other pharmacokinetic parameters (Q2 and V2).

Table 3 lists all parameter estimates including their coefficient of variation values and OFVs of the simple model (model A) and the final model (model E). The observed vs. population-predicted plots stratified by the different cohorts in Figure 3 confirm that the final model describes not only the study population as a whole but also the individual study populations without bias. The stability of the final model was shown by the bootstrap analysis (Table 3).

Figure 4 shows population propofol clearance values vs. age for different TBWs using the final model (model E). This figure shows both the allometric increase of propofol clearance with TBW as the distance between the weight classes decreases with increasing TBW, and the bilinear relationship of propofol clearance with age.

**DISCUSSION**

To describe the influence of obesity and age on the pharmacokinetics of propofol, a population pharmacokinetic meta-analysis was performed using data from morbidly obese adults, adolescents, and children and their nonobese controls. In this study, a wide range of TBW (37–184 kg) and age (9–79 years) was studied, with data from (morbidly) obese and nonobese individuals in each age range. The results of the systematic analysis shows that a combination of TBW and age proved to best capture changes in propofol clearance as a result of obesity and ageing. Although it is yet unknown how these results should be put in physiological perspective, the current model seems to provide the best description of the data from these largely divergent patient populations.

In recent reports in (morbidly) obese adults, it was shown that the increase in propofol clearance was related to TBW and could be best described using an allometric function. In addition, an allometric relationship between TBW and propofol clearance was found in a data set of morbidly obese adolescents. Allometric scaling factors of 0.72 (ref. 6) and 0.80 (ref. 7) were estimated for morbidly obese adults and children and adolescents, respectively. As these factors are close to the factor of 0.75 predicted by allometry theory, this implies that obese individuals can be viewed as "large individuals" (a different body size)

Table 3 Population pharmacokinetic parameter estimates for the simple and the final pharmacokinetic model for propofol in nonobese and (morbidly) obese children, adolescents, and adults including the bootstrap values of the final model

| Parameter | Simple model | Final model | Bootstrap final model |
|-----------|--------------|-------------|----------------------|
|           | Mean (CV%)   | Mean (CV%)  | Mean (CV%)           |
| Model     | A            | E           | –                    |
| Number of patients | 94          | 94          | 250                  |
| CL (l/min) | 2.37 (3.8)  | –           | –                    |
| CL70 kg−41 years (l/min) | –          | 2.34 (4.3) | 2.31 (4.6)           |
| z         | –            | 0.77 (6.9)  | 0.77 (7.4)           |
| b         | –            | 0.0103 (13.5)| 0.0094 (18.5)       |
| d         | –            | −0.00539 (−33.8)| −0.00485 (−39.7) |
| V1 (L)    | 3.33 (11.5)  | 3.17 (11.3) | 3.16 (10.0)          |
| V2 (L)    | 6.55 (14.5)  | 5.89 (15.0) | 5.78 (15.3)          |
| V3 (L)    | 118 (9.1)    | 116 (7.5)   | 117 (6.7)            |
| Q2 (l/min)| 1.74 (9.7)   | 1.60 (11.7) | 1.57 (12.2)          |
| Q3 (l/min)| 2.00 (7.6)   | –           | –                    |
| Q370 kg−41 years (l/min) | –          | 1.50 (6.2)  | 1.46 (5.0)           |
| Interindividual variability (%) | 35.1 (15.5) | 17.5 (13.9) | 17.7 (12.6)          |
| CL        | 46.6 (44.4)  | 50.6 (41.3) | 51.1 (38.8)          |
| V1        | 40.4 (42.0)  | 36.2 (34.9) | 35.4 (27.8)          |
| V3        | 48.1 (42.3)  | 40.4 (37.5) | 35.1 (34.4)          |
| Proportional intraindividual error (%) | 24.3 (10.4)| 24.3 (10.3) | 24.1 (11.1)          |
| OFV       | −2,331       | −2,474      | −2,500               |

\[CL = CL70 kg \times (TBW/70)^b \times F_{age}\]

\[\text{Age} \leq 41 \text{ y: } F_{age} = (1 + b \times (\text{age} - 41)) \text{ and } \text{Age} > 41 \text{ y: } F_{age} = (1 + c \times (\text{age} - 41)).\]

\[Q3 = Q3_{70 kg} \times (TBW/70)^b\]

b, age factor for clearance age ≤ 41 years; c, age factor for clearance age > 41 years; CL, clearance; CL70 kg−41 years, population mean value for clearance in an individual of 70 kg; CL70 kg−41 years, population mean value for clearance in an individual of 70 kg and 41 years; CV, coefficient of variation of the parameter values; F_{age}, age factor for clearance; OFV, objective function value; Q2, compartmental clearance between V1 and V2; Q3, compartmental clearance between V1 and V3; Q370 kg, population mean value for compartmental clearance between V1 and V3 in an individual of 70 kg; V1, central volume of distribution; V2, peripheral volume 1; V3, peripheral volume 2; z, allometric scaling factor in CL = CL70 kg \times (TBW/70)^b.\]
in children, correlated clearance; TBW and E). This difference in propofol clearance could be described with two separate functions for propofol clearance; i.e., one equation for children and adolescents and one equation for adults (model C). Alternatively and significantly better, age was incorporated as covariate on propofol clearance using a bilinear function (models D and E). Therefore, in the final model, the influence of age and obesity on propofol clearance was described using both TBW and age as covariates for propofol clearance. This final equation (Eq. 1) is independent of the definitions for age (e.g., adolescents and adults) and obesity (e.g., obese and morbidly obese) categories and might prove useful for clinical practice.

In this study, there was no significant relationship between body size measures and volumes of distribution. Previously, age and TBW have been identified as covariates for volumes of distribution of propofol in nonobese and obese patients.\textsuperscript{5,13,14} As a result of the finding that LBW correlated with V1, Ingrande et al.\textsuperscript{15} suggested to use LBW for the induction of anesthesia with propofol. The lack of significant influence of LBW on volume of distribution in our analysis may be explained by the fact that the studies included in the current analysis mainly contained observations following propofol maintenance infusions. As such, these data sets did not contain sufficient observations just after the induction bolus dose of propofol to adequately describe early (re-)distribution and the influence of covariates on volumes of distribution. It therefore seems that additional research is needed to characterize covariates predictive of volume of distribution that will allow estimation of propofol-loading doses in morbidly obese adults and children.

This study had a few limitations. We investigated a cohort of children and adolescents with a lower age limit of 9 years. In clinical practice, propofol is administrated to even

Figure 3 Observed vs. population-predicted propofol concentrations of the final model (model E). Panels represent data of morbidly obese adults, nonobese adults, morbidly obese children and adolescents, and nonobese children and adolescents. The solid gray line represents the line of identity, y = x.

Figure 4 Model-based predictions of population clearance estimates of propofol vs. age for patients with different total body weights.
younger children, and therefore, more research is needed to investigate if the current findings are also applicable for children younger than 9 years. In addition, the pharmacodynamics of propofol were not included in the current analysis. Obesity influenced the pharmacodynamics of propofol in children and adolescents using propofol. Underlying diseases such as diabetes and a changed (patho)physiology in (morbidly) obese patients may also influence the pharmacodynamics of propofol. To develop dosing algorithm for propofol in morbidly obese adults, children, and adolescents, an integrated pharmokinetic and pharmacodynamic meta-analysis is urgently needed.

It remains to be speculated how the influence of TBW on propofol clearance that was found in our study can be explained. Studies have shown that obese patients suffer from low-grade inflammation, which is probably the underlying cause of the high prevalence of nonalcoholic steatohepatitis. It is known that nonalcoholic steatohepatitis increases fat deposition in the liver causing sinusoidal narrowing and altered functional morphology of the liver. By contrast, because of increased blood volume and cardiac output, hepatic blood flow is possibly increased in obese subjects. As a result, increased propofol clearance may be anticipated as propofol is a high extraction ratio drug mainly metabolized by various UDP-glucuronosyltransferase enzymes. Data on other high-extraction drugs and drugs metabolized by UDP-glucuronosyltransferase suggest that both UDP-glucuronosyltransferase activity and liver blood flow are increased in obese adults. Furthermore, UDP-glucuronosyltransferase activity is increased in obese adolescents as compared with nonobese adolescents. Even though this cannot be proven, it can be hypothesized that hepatic blood flow is even more increased due to prolonged duration of obesity in adults as compared with adolescents with the same TBW. This is supported by the fact that age could be incorporated as a covariate on propofol clearance. As propofol clearance is limited by the blood flow through the liver, the effect of both TBW and age on propofol may be explained by changes in liver blood flow.

In this pharmacokinetic meta-analysis, we developed a model for scaling propofol clearance over wide ranges of TBW and age using data from morbidly obese adults, adolescents, and children and their nonobese controls. The results show that TBW was the most predictive covariate for propofol clearance among patients when implemented as an allometric function. In addition, age was incorporated using a bilinear function with two distinct slopes, reflecting an initial increase and subsequent decrease in clearance as a result of age. Using these two functions, the influence of both (over) weight and age on propofol clearance was well characterized, which may provide a basis for dosing across this diverse group of patients.

METHODS

Patients. Data of five previously published studies were used for this analysis. Patient characteristics of the five different studies are provided in Table 1. Details of the studies are briefly summarized when relevant to the current analysis. Morbidly obese adults. Twenty morbidly obese adults scheduled for bariatric surgery with a mean TBW of 124 kg (range: 98–167 kg) received either a propofol induction dose of 200 or 350 mg. Maintenance propofol infusion rate was initiated at 10 mg/kg times TBW/h and adjusted to keep Bispectral index values between 40 and 60. Remifentanil continuous infusion was administered 25 µg/h/kg based on ideal body weight. Multiple blood samples were collected before the start of the propofol bolus until 150 min after the end of the infusion.

Nonobese adults. Forty nonobese adults with a mean TBW of 74 kg (range: 55–98 kg) were included. Twenty-four female patients received a bolus injection of 2.5 mg/kg of propofol for induction of anesthesia while anesthesia was maintained with isoflurane. Following onset of unconsciousness, fentanyl (0.003–0.005 mg/kg) was administered and as required additional amounts of 50–100 mg. Blood samples were collected from 1 min until 180 min after the induction dose of propofol. Of these 24 patients, only 20 patients were in this study because height measure of 4 patients was not available. Another 20 nonobese intensive care patients received continuous propofol infusions for 2–5 days with propofol doses based on the Ramsay six-point-scale morphine administration as an analgesic was given when the patient was considered to be in pain (seven patients; each patient received morphine as a continuous infusion of 40–50 mg/day). Blood samples were collected four times daily during propofol maintenance infusion for 2–5 days.

Morbidly obese children and adolescents. In 20 morbidly obese adolescents and children scheduled for bariatric surgery with mean TBW of 125 kg (range: 70–184 kg) and mean age of 16 years (range: 9–18 years), propofol was administered using dosing weight calculated according to the method of Servin et al. Fentanyl 100 µg was administered just after the induction, and 50 µg doses were administered in case of inadequate analgesia. Blood samples were collected before the start of the propofol infusion and from 15 min after the start of infusion until 120 min after the end of the infusion.

Nonobese children and adolescents. In 14 nonobese adolescents and children with mean TBW of 54 kg (range: 37–82 kg) and a mean age of 14 years (range: 9–20 years), anesthesia was induced with a bolus dose of propofol (4 mg/kg) and maintained with propofol by continuous infusion (2–10 mg/kg/h) and remifentanil (0.2–1 µg/kg/min) for scoliosis surgery. Blood samples were taken before induction of anesthesia, and at ~15 or 30 min after the start of propofol infusion until 120 min after the end of the infusion.

Data analysis and internal validation. The analysis was performed by means of nonlinear mixed-effects modeling using NONMEM (version VI, release 1.1; GloboMax LLC, Hanover, MD) with S-plus (version 6.2; Insightful Software, Seattle,
WA) to visualize the data. Discrimination between different models was made by comparison of the OFV (−2 log likelihood (OVL)). A value of P < 0.05, representing a decrease of 3.8 in the OVL, was considered statistically significant. In addition, goodness-of-fit plots (observed vs. individually predicted, observed vs. population predicted, conditional weighted residuals vs. time, and conditional weighted residuals vs. population predictions) were used for diagnostic purposes. Furthermore, the confidence interval of the parameter estimates, the correlation matrix, and visual improvement of the individual plots were used to evaluate the model. η-shrinkage as defined by Karlsson et al. was calculated for all model parameters for which interindividual variability was estimated. The internal validity of the population pharmacokinetic models was assessed by a per-study stratified bootstrap resampling method using 250 replicates. Validation using external data sets was not part of the current analysis.

Pharmacokinetic model. Log-transformed propofol concentration data were described by a three-compartment model (NONMEM VI, ADVAN11, and TRANS4) parameterized in terms of volume of distribution of the central (V1), first (V2), and second peripheral compartments (V3), intercompartmental clearance from the central to the first peripheral compartment (Q2) and from the central to the second peripheral compartment (Q3), and clearance from the central compartment (CL).

The interindividual value (post hoc value) of the parameters of the ith subject was modeled by the following formula:

\[ \theta_i = \theta_{mean} \cdot e^{\eta_i} \]  

(2)

where \( \theta_{mean} \) is the population mean and \( \eta_i \) is a random variable with mean zero and variance \( \omega^2 \), assuming lognormal distribution in the population.

The intrasubject variability, resulting from assay errors, model misspecifications, and other unexplained sources, was best described with a proportional error model. This means for the ith observed log-transformed propofol concentration of the ith individual, the relation \( Y_i \):

\[ Y_i = \log c_{pred,i} + \varepsilon_i \]  

(3)

where \( c_{pred,i} \) is the predicted propofol concentration and \( \varepsilon_i \) is the random variable with mean zero and variance \( \sigma^2 \).

Covariate analysis. Covariates were plotted independently against the individual post hoc parameter estimates of all pharmacokinetic parameters and the conditioned weighted residuals to visualize potential relations. The following covariates were tested: TBW, body mass index, ideal body weight and LBW, gender, and age. Covariates were tested using linear and power equations:

\[ P_i = P_{\text{pp}} \left( \frac{\text{Cov}}{\text{Cov}_{\text{standard}}} \right) ^ z \]  

(4)

where \( P_i \) and \( P_{\text{pp}} \) represent individual and population parameter estimates, respectively, Cov represents the covariate, and \( \text{Cov}_{\text{standard}} \) represents a standardized (i.e., 70 kg for TBW) or median value of the covariate for the population. \( z \) represents the scaling factor, which was fixed to 1 for a linear function or an estimated value for a power equation.

The influence of the covariate age on clearance was also tested using a bilinear function with two distinct slopes, i.e., a linear increase in clearance for age values below the median age and a linear decrease in clearance for age values higher than the median age (Eq. 5).

\[ CL_i = CL_{pp} \times F_{\text{age}} \]  

\[ F_{\text{age}}(\text{age} \leq \text{median age}) = \begin{cases} \text{1+ a × (age in years)} \\ \text{median age in years} \end{cases} \]

\[ F_{\text{age}}(\text{age} > \text{median age}) = \begin{cases} \text{1+ c × (age in years)} \\ \text{median age in years} \end{cases} \]  

(5)

Potential covariates were separately entered into the model and statistically tested by use of the OFV and if applicable the 95% confidence interval of the additional parameter. A P < 0.005 was applied to evaluate the covariates in the forward inclusion (OFV decrease > 7.9), whereas the backward deletion procedure used a stricter criterion (OFV decrease > 10.8; P < 0.001). When more than one significant covariate for the simple model was found, the covariate-adjusted model with the largest decrease in objection function was chosen as a basis to sequentially explore the influence of additional covariates using the same criteria. Finally, after forward inclusion, a backward exclusion procedure was applied to justify the covariate. The choice of the covariate model was further evaluated as discussed under the section Data analysis and internal validation.

Acknowledgments. The authors acknowledge the Teen Longitudinal Assessment of Bariatric Surgery team at Cincinnati Children’s Hospital Medical Center (www.TeenLABS.org) for their support during this study. This study was funded by the Translational Research Initiative grant from Cincinnati Children’s Research Foundation, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. The authors also acknowledge financial support from National Institutes of Health grant 1K24HD050387 (A.A.V.). The authors thank Simone van Kralingen for executing the study that was used in this meta-analysis and Uppsala Pharmacometric Summer School 2012 for helping to analyze the data.

Author Contributions. J.D., V.C., S.S., B.v.R., E.P.A.v.D., A.A.V., and C.A.J.K. wrote the manuscript. J.D., V.C., S.S., H.J.B.v.O-A., T.I., B.v.R., E.P.A.v.D., A.A.V., and C.A.J.K. designed the research. J.D., V.C., S.S., H.J.B.v.O-A., T.I., and E.P.A.v.D. performed the research. J.D., A.A.V., and C.A.J.K. analyzed the data.

Conflict of Interest. The authors declared no conflict of interest.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✓ There is very limited knowledge on how key pharmacokinetic parameters such as clearance change in morbidly obese children, adolescents, and adults as compared with their nonobese counterparts.

WHAT QUESTION DID THIS STUDY ADDRESS?
✓ This study characterizes the influence of both morbid obesity and age on the pharmacokinetics of propofol using data from patients varying in TBW from 37 to 184 kg and in age from 9 to 79 years.

WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✓ Propofol clearance increased with TBW in an allometric function, whereas age was found to influence clearance in a bilinear fashion with two distinct slopes, reflecting an initial increase and subsequent decrease as a result of aging.

HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS
✓ While the proposed pharmacokinetic model was the best description of the available data, the results can be used to further explore physiological explanations for the findings.

1. Ogden, C.L., Carroll, M.D., Curtin, L.R., Lamb, M.M. & Flegal, K.M. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303, 242–249 (2010).
2. Eleveld, D.J., Proost, J.H., Abi-Akoul, A.R. & Struys, M.M. Obese and allometric scaling of pharmacokinetics. Clin. Pharmacokinet. 50, 751–753; discussion 755 (2011).
3. Han, P.Y., Duffull, S.B., Kirkpatrick, C.M. & Green, B. Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Ther. 82, 505–508 (2007).
4. Wang, C. et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm. Res. 29, 1570–1581 (2012).
5. Cortinez, L.I. et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br. J. Anaesth. 105, 448–456 (2010).
6. van Kralingen, S. et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin. Pharmacokinet. 50, 739–750 (2011).
7. Depstraten, J. et al. Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin. Pharmacokinet. 51, 543–551 (2012).
8. Pal, M.P. & Paloucek, F.P. The origin of the “ideal” body weight equations. Ann. Pharmacother. 34, 1068–1069 (2000).
9. Jammahasatian, S., Duffull, S.B., Ash, S., Ward, L.C., Byrne, N.M. & Green, B. Quantification of lean body weight. Clin. Pharmacokinet. 44, 1051–1065 (2005).
10. Peters, A.M., Stenling, H.L., Glass, D.M. & Bird, N.J. Estimation of lean body mass in children. Br. J. Anaesth. 106, 719–723 (2011).
11. Savic, R.M. & Karlsson, M.O. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 11, 558–569 (2009).
12. Anderson, B.J. & Holliday, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 333–352 (2008).
13. Schütter, J. & Ihmense, H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 92, 727–738 (2000).
14. Servin, F., Fairnotti, R., Haberer, J.P. & Desmonts, J.M. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacological study. Anesthesiology 78, 657–665 (1993).
15. Ingande, J., Brodsky, J.B. & Lemmens, H.J. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth. Analg. 113, 57–62 (2011).
16. Otayo, O.A. et al. The effect of obesity on the ED(95) of propofol for loss of consciousness in children and adolescents. Anesth. Analg. 115, 147–153 (2012).
17. Adams, J.P. & Murphy, P.G. Obesity in anaesthesia and intensive care. Br. J. Anaesth. 85, 91–108 (2000).
18. Welling, K.E. & Hotamisligil, G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111–1119 (2005).
19. Guzzalino, G., Gugini, G., Mincoci, A., Moro, D. & Morabito, F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glyceremic and insulinemic responses to an oral glucose tolerance test. Int. J. Obes. Relat. Metab. Disord. 24, 772–778 (2000).
20. Farrell, G.C., Tech, N.C. & McCuekey, R.S. Hepatic microcirculation in fatty liver disease. Anat. Rec. (Hoboken) 291, 684–692 (2012).
21. Casati, A. & Putzu, M. Anesthesia in the obese patient: pharmacokinetic considerations. J. Clin. Anesth. 17, 134–145 (2005).
22. Al-Jahdat, W.S., Yamamoto, K., Hlava, H., Nakamura, K., Goto, F. & Horuchi, R. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. Eur. J. Clin. Pharmacol. 57, 527–533 (2006).
23. Kiang, T.K., Erosg, M.H. & Chang, T.K. UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol. Ther. 106, 97–132 (2005).
24. Abernethy, D.R., Divo, M., Greenblatt, D.J. & Ameer, B. Obesity, sex, and acetylation disposition. Clin. Pharmacol. Ther. 31, 783–790 (1982).
25. van Want, S. et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 48, 4766–4777 (2004).
26. Abernethy, D.R., Greenblatt, D.J., Divo, M. & Shadi, R. I. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J. Lab. Med. 101, 57–62 (2012).
27. Sparreboom, A. et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J. Clin. Oncol. 25, 4707–4717 (2007).
28. Schwartz, A.E., Matteo, R.S., Omstein, E., Young, W.L. & Myers, K.J. Pharmacokinetics of suferon in obese patients. Anesth. Analg. 73, 790–793 (1991).
29. Barshop, N.J., Capparelli, E.V., Sirlin, C.B., Schwimmer, J.B. & Levine, J.E. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 52, 198–202 (2011).
30. Kribbe, C.A. et al. Pharmacokinetics, induction of anaesthessia and safety characteristics of propofol 6% SADN vs propofol 1% SADN and Diprivan-10 after bolus injection. Br. J. Clin. Pharmacol. 47, 655–660 (1999).
31. Kribbe, C.A., Zuiveveld, K.P., De Jongh, J., Kukk, P.F., Aarts, L.P. & Danhof, M. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin. Pharmacol. Ther. 72, 670–684 (2002).
32. Peeters, M.V. et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin. Pharmacokinet. 49, 269–275 (2010).
33. Beal, S.L., Sheiner, L.B., Boeckmann, A. NONMEM User’s Guide. (University of California, San Francisco, 1999).
34. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17–20 (2007).
35. Jonsson, E.N. & Karlsson, M.O. Automated covariate model building within NONMEM. Pharm. Res. 15, 1463–1466 (1998).